Immersive Virtual Reality During Robot-assisted Walking.
The Use of Immersive Virtual Reality During Robot-assisted Walking in Healthy Adults - Effect of Changing the Optic Flow Speed in Two Different Virtual Environments on Active Participation During Robot-assisted Walking.
The aim of this study is to investigate the effect of manipulating the optic flow (OF) speed in 2 different virtual environments (VE) on active participation in healthy participants during virtual reality (VR) - enhanced robot-assisted gait(RAG).
The second aim is to investigate the effect of two different VEs on active participation during RAG.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
STUDY DESIGN: an experimental, 2-group, single-center trial will be conducted in which healthy participants will perform one VR-enhanced RAG session in which 3 different OF speeds will be presented in a random order: 1) walking with slow OF speed, 2) walking with matched OF speed, and 3) walking with fast OF speed. The VE will be different for both groups. The experimental group will have a stimulus rich VE that represents a park where subjects will walk through. This VE will be more interactive by allowing other avatars or animals to walk through the VE. The control group will have a stimulus poor VE that represents an endless hallway. Since the subjects will walk alone in the hallway for the entire time, this VE will be less interactive.
PATIENT RECRUITMENT: we aim to recruit 28 healthy participants, divided equally into two groups. In case subjects drop out, additional participants will be tested till 14 participants in each group completed all conditions.
PROCEDURE: Participants will be tested during one VR-enhanced RAG session at the rehabilitation center TrainM (Antwerp). Prior to the start of the experiment, surface electrodes will be placed bilateral on the Mm. rectus femoris and Mm. biceps femoris to measure muscle activity. Electrode placement will follow as closely as possible the guidelines of SENIAM. The skin underlying the electrode will be shaved and cleaned to improve electrode-skin contact and reduce impedance. At the start of the session, participants will be habituated to walking in the Lokomat without the VR. During this habituation trial, the appropriate settings to walk comfortable in the exoskeleton will be determined. To make sure all participants will walk comfortable in the Lokomat, subjects will be provided with a body weight support (BWS) of 30%. Guidance Force (GF) will be set on 80% for all participants. With lower levels of GF, the biofeedback values will show smaller changes and can become negligible. Lastly, the walking speed (WS) will be set at 2.8 km/h for all participants. Preparing and installing the participant and determining the appropriate Lokomat settings will take no longer than 20 minutes. When the Lokomat settings are defined, the Lokomat will be stopped for a moment so that the VR can be added. Participants will put on the head-mounted display (HMD) and will start walking again for one minute while watching the VE scene expanding at a speed matching their walking speed to get used to the VR. After the habituation trial, participants will walk in the Lokomat with the three different OF speeds that will be presented in a random order for 7 minutes each:
- slower OF: 0.5 times the individual's WS,
- matched OF: same as the individual's WS,
- faster OF: 2 times the individual's WS.
In order to normalize the registered EMG signals, the maximum voluntary isometric contraction (MVIC) test will be used. Each subject carries out the MVIC test 3 times for each muscle. Subjects must reach their maximum strength as quickly as possible and must keep it for 6 seconds. Subjects will perform the MVIC test in the following testing positions: prone with the knees in 30° of flexion (Mm. biceps femoris); seated with the knees in 60°of flexion, and the hips in 90° of flexion (Mm. rectus femoris). The average of the three tests will be taken for each muscle.
RANDOMIZATION: Subjects who agree to participate in this study will be equally randomized in a 1:1 ratio into 2 groups. For randomization, sealed envelopes will be prepared in advance and marked on the inside with a VE + or VE -. During the intervention, the speed of the OF (slow, matched or fast) will also be randomized. To participants, it will only be said that they will have to walk in the Lokomat with the VR for 21 minutes. They will not know that and when the speed of the OF will change.
MATERIALS: The VR will be provided with the use of a novel HMD VR system 'Oculus Rift' (Oculus Rift, LLC, US). The Oculus Rift promises the user more immersion and visual clarity of the virtual rendered world, by use of a custom display and optics technology designed specifically for VR.
Surface EMG electrodes will be used to measure the muscle activity of the Mm. rectus femoris and Mm. biceps femoris. Surface EMG data will be captured with the ME6000 EMG-system (Mega Electronics Ltd) using Conmed Cleartrace electrodes (Ag/AgCl) with an active diameter of 10mm.
The Lokomat has a biofeedback system that measures and displays participants' activity in real-time. With the use of force sensors, this biofeedback system measures the torques acting onto the corresponding Lokomat joint. This is calculated from the signals of the force sensors in the drives. Positive values correspond to external forces (from the subject) acting into flexion direction, while negative values correspond to external forces (from the subject) acting into extension. Besides force sensors, the Lokomat also comprises position sensors. These sensors will be used to measure the range of motion (ROM) of the hip- and knee joints. A value of 0 corresponds to a neutral position, positive values corresponds to flexion and negative values to extension.
STATISTICAL ANALYSIS: Statistics will be performed using SPSS (IBM, Chicago, IL). The significance level will be set on 5%. Descriptive statistics will be calculated for baseline participant characteristics. Means and standard deviations will be calculated for continues variables and frequencies and percentages for categorical variables. Active participation will be determined with the use of muscle activity (EMG), interaction torques and range of motion and will be measured continuously during the session. Data analysis of the average of every minute will be conducted. To investigate the effect of time, the different OF speeds, and the different VEs, repeated-measures ANOVA (within-between subject design) will be analyzed.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Antwerp、ベルギー、2018
- Rehabilitation center TrainM
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy persons ≥ 55 years of age,
- Normal or corrected-to-normal vision with glasses or contact lenses,
- No locomotion impairments,
- A maximal body weight of 135 kg,
- A maximal body height of 200 cm
Exclusion Criteria:
- Skin lesions that cannot be protected appropriately,
- Significant lower extremity injuries during the last two years that might affect their gait,
- Any type of vestibular/visual deficiency
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Stimulus rich VE
Participants will be tested during 1 RAG session in the Lokomat.
Participants in the experimental group will walk in a stimulus rich VE such as walking in a park.
|
Participants will walk in the Lokomat with the VR for 21 minutes.
After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
|
|
アクティブコンパレータ:Stimulus poor VE
Participants will be tested during 1 RAG session in the Lokomat.
Participants in the control group will walk in a stimulus poor VE, such as walking through an endless hallway.
|
Participants will walk in the Lokomat with the VR for 21 minutes.
After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Muscle activity (EMG)
時間枠:Every minute of the 21-minute session.
|
Muscle activity will be measured continuously during the 21 minutes of testing.
Average muscle activity (%MVIC) will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Interaction torques left hip
時間枠:Every minute of the 21-minute session.
|
Interaction torques will be measured continuously during the 21 minutes of testing.
Average interaction torques (Nm) between participant and device will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Interaction torques left knee
時間枠:Every minute of the 21-minute session.
|
Interaction torques will be measured continuously during the 21 minutes of testing.
Average interaction torques (Nm) between participant and device will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Interaction torques right hip
時間枠:Every minute of the 21-minute session.
|
Interaction torques will be measured continuously during the 21 minutes of testing.
Average interaction torques (Nm) between participant and device will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Interaction torques right knee
時間枠:Every minute of the 21-minute session.
|
Interaction torques will be measured continuously during the 21 minutes of testing.
Average interaction torques (Nm) between participant and device will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Range of motion left hip
時間枠:Every minute of the 21-minute session.
|
Range of motion will be measured continuously during the 21 minutes of testing.
Average range of motion (°) will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Range of motion left knee
時間枠:Every minute of the 21-minute session.
|
Range of motion will be measured continuously during the 21 minutes of testing.
Average range of motion (°) will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Range of motion right hip
時間枠:Every minute of the 21-minute session.
|
Range of motion will be measured continuously during the 21 minutes of testing.
Average range of motion (°) will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
|
Range of motion right knee
時間枠:Every minute of the 21-minute session.
|
Range of motion will be measured continuously during the 21 minutes of testing.
Average range of motion (°) will be measured at different time frames.
Offline calculation (e.g.
averages) will be performed afterwards.
|
Every minute of the 21-minute session.
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Emma De Keersmaecker, Ph.D student、Vrije Universiteit Brussel
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- Lokomat study with VR - I
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Stimulus rich VEの臨床試験
-
NCT05530967まだ募集していません